- Home
- CNEY vs ENTO Comparison
CNEY vs ENTO Comparison
Compare CNEY & ENTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNEY
- ENTO
- Stock Information
- Founded
- CNEY 2018
- ENTO 2014
- Country
- CNEY China
- ENTO United States
- Employees
- CNEY N/A
- ENTO N/A
- Industry
- CNEY Major Chemicals
- ENTO Biotechnology: Pharmaceutical Preparations
- Sector
- CNEY Industrials
- ENTO Health Care
- Exchange
- CNEY Nasdaq
- ENTO Nasdaq
- Market Cap
- CNEY 2.1M
- ENTO 2.3M
- IPO Year
- CNEY 2021
- ENTO 2016
- Fundamental
- Price
- CNEY $2.76
- ENTO $0.39
- Analyst Decision
- CNEY
- ENTO
- Analyst Count
- CNEY 0
- ENTO 0
- Target Price
- CNEY N/A
- ENTO N/A
- AVG Volume (30 Days)
- CNEY 58.5K
- ENTO 852.3K
- Earning Date
- CNEY 01-01-0001
- ENTO 05-15-2025
- Dividend Yield
- CNEY N/A
- ENTO N/A
- EPS Growth
- CNEY N/A
- ENTO N/A
- EPS
- CNEY N/A
- ENTO N/A
- Revenue
- CNEY $50,957,974.00
- ENTO N/A
- Revenue This Year
- CNEY N/A
- ENTO N/A
- Revenue Next Year
- CNEY N/A
- ENTO N/A
- P/E Ratio
- CNEY N/A
- ENTO N/A
- Revenue Growth
- CNEY N/A
- ENTO N/A
- 52 Week Low
- CNEY $2.53
- ENTO $0.19
- 52 Week High
- CNEY $40.00
- ENTO $1.54
- Technical
- Relative Strength Index (RSI)
- CNEY 44.63
- ENTO 44.28
- Support Level
- CNEY $2.58
- ENTO $0.45
- Resistance Level
- CNEY $2.87
- ENTO $0.57
- Average True Range (ATR)
- CNEY 0.18
- ENTO 0.07
- MACD
- CNEY 0.03
- ENTO -0.01
- Stochastic Oscillator
- CNEY 41.82
- ENTO 3.77
About CNEY CN Energy Group Inc.
CN Energy Group Inc along with its subsidiaries is a manufacturer and supplier of wood-based activated carbon that is used in pharmaceutical manufacturing, industrial manufacturing, water purification, environmental protection, and food and beverage production and a producer of biomass electricity generated in the process of producing activated carbon. The firm generates a majority of its revenue from Activated carbon.
About ENTO Entero Therapeutics Inc. Common Stock
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.